Increasing evidence demonstrates that alteration in intrauterine environment programs the development of chronic diseases later in life \[[@B1]\]. For example, we previously showed that fetal exposure to maternal diabetes is associated to altered glucose-stimulated insulin secretion at an adult age \[[@B2], [@B3]\]. However, there are fundamental aspects of the control of glucose homeostasis that are regulated differently in males and females \[[@B4]\]. Indeed, the prevalence of prediabetic syndromes such as impaired fasting glucose is more prevalent in men, whereas impaired glucose tolerance is more prevalent in women, which is reviewed in Mauvais-Jarvis \[[@B4]\]. Whether fetal exposure to maternal diabetes predisposes to alteration in insulin secretion in a sexually dimorphic manner is unknown. To address this issue, we studied oral and intravenous (IV) glucose-stimulated insulin secretion in adult male and female offspring following fetal exposure to maternal diabetes.

1. Subjects and Methods {#s1}
=======================

Fifty-eight (27 males, 31 females), aged ≥18 years, offspring of type 1 diabetic (T1D) subjects (as defined by the American Diabetes Association), born at least two years after parental diagnosis of diabetes were included in the study \[[@B5], [@B6]\]. These offspring had no diabetes, no family history of type 2 diabetes, and were free from immune marker of T1D. Offspring exposed to maternal T1D during pregnancy (ODM) were compared with offspring of T1D fathers (ODF) as controls. The study was approved by the ethical committee of Paris Saint-Louis Hospital, and all participants gave written informed consent.

At the first visit, a 75-g oral glucose tolerance test was performed after a 12-hour overnight fast with blood samples collected at times 0, 30, and 120 minutes for glucose and insulin measurement. Percent body fat was measured by dual-energy X-ray absorptiometer (LUNAR iDXA, ME+ 200027, GE Health Care) and fat mass, and fat-free mass were calculated.

Within a week after the first visit, we performed a 100-minute euglycemic hyperinsulinemic clamp at 80 mU/m^2^/min insulin infusion to measure insulin-stimulated glucose disposal rate (M value), whereas blood glucose was clamped at 100 mg/dL (5.56 mol/L) \[[@B3], [@B7]\]. The clamp was followed by a graded IV glucose infusion (glucose ramping) consisting of four consecutive 40-minute IV infusion periods of 20% glucose at 4, 8, 12, and 16 mg/kg of body weight per minute. Then, the 20% glucose infusion rate was adjusted to obtain a blood glucose level of approximately 400 mg/dL (22 mmol/L). Glucose infusion was then maintained and an IV bolus of 5 g of arginine chlorhydrate was administered in 45 seconds, with venous blood sample collection before and 2, 3, 4, 5, 10, and 15 minutes after the bolus.

A. Calculations {#s2}
---------------

The insulinogenic index (*Δ*insulin0-30/*Δ*glucose0-30) was used to estimate early insulin secretion during oral glucose tolerance test. Insulin secretion rate (ISR) during glucose ramping was calculated by deconvolution of the C-peptide \[[@B8]\] and plotted against the corresponding mean glucose concentration. The dose-response effect of glucose on ISR and glucagon secretion inhibition during glucose ramping was estimated by comparing the slope of ISR or glucagon levels as a function of glucose levels. The incremental area under the curve (AUCI) of insulin and glucagon levels during the first 5 minutes (AUCI-5) and the whole 15 minutes (AUCI-15) of the arginine test were calculated using the trapezoidal rule. We also determined the acute insulin and glucagon responses to arginine as the mean of the 2-, 3-, 4-, and 5-minute plasma levels minus the basal (prearginine) plasma concentration \[[@B9]\]. The M value was calculated according to DeFronzo *et al.,* after accounting for interindividual differences in glucose space, and was expressed in milligrams per kilogram of fat-free mass per minute \[[@B10]\]. We also calculated the insulin sensitivity index as the ratio of M value to the mean insulin concentration during the last 20 minutes of the euglycemic hyperinsulinemic clamp.

Statistical analysis was performed using R 2.6.2 (The R Foundation for Statistical Computing, Vienna, Austria). The relationship between ISR or glucagon and glucose levels during glucose ramping was analyzed using mixed-model analysis of covariance. Fixed effects in the model included body mass index, a linear and a quadratic effect for glucose levels, a fetal exposure group effect (ODMs vs ODFs), a sex effect, and their interactions. Random subject effects (intercept and slopes) were added to the models. In response to arginine, adjustment for prestimulus insulin and glucose levels was done. All tests were two-sided and the level of significance was set at *P* \< 0.05.

2. Results {#s3}
==========

The characteristics of the offspring studied and their parents are shown in [Table 1](#T1){ref-type="table"}. There was no substantial difference between ODMs and ODFs with respect to anthropometric variables, routine laboratory tests, and insulin sensitivity. In response to oral glucose, the early insulin secretion was decreased in ODMs compared with ODFs ([Table 2](#T2){ref-type="table"}, [Fig. 1A](#F1){ref-type="fig"}; *P* = 0.035). During the graded IV glucose infusion, the ISR was similar in ODMs and ODFs ([Table 2](#T2){ref-type="table"}). However, a significant interaction between group and offspring sex was found for the slope of ISR against plasma glucose (*P* = 0.03), indicating that ISR was lower and slower in female ODMs compared with female ODFs ([Fig. 1B](#F1){ref-type="fig"}). During the graded IV glucose infusion, female ODMs also tended to exhibit reduced glucagon suppression by glucose compared with female ODFs (*P* = 0.07; [Fig. 1C](#F1){ref-type="fig"}). In contrast, in response to combined glucose and arginine, insulin and glucagon secretion were similar in ODFs and ODMs with no sex effect ([Table 2](#T2){ref-type="table"}).

###### 

Participant Characteristics by Group and Sex

                                                 ODF (n = 29)       ODM (n = 29)                                             
  ---------------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------------------------------
  Diabetic parent characteristics                                                                                            
   Current age, mean (SD), y                     57.0 (6.2)         57.7 (7.4)         53.1 (6.1)         55.2 (7.2)         0.083
   Age at diabetes onset, mean (SD), y           16.7 (8.5)         19.3 (8.6)         16.7 (8.7)         14.4 (7.4)         0.26
   Age at offspring birth, mean (SD), y          30.4 (5.7)         31.8 (3.7)         27.5 (3.4)         28.2 (4.1)         0.006
   Current body-mass index, mean (SD), kg/m^2^   26.6 (4.5)         24.2 (2.8)         24.7 (5.1)         25.8 (3.1)         0.90
   Nephropathy, no. (%)                          3 (21)             3 (21)             1 (8)              3 (20)             0.51
   Retinopathy, no. (%)                          13 (93)            12 (80)            9 (69)             11 (73)            0.18
   Macroangiopathy, no. (%)                      6 (43)             0 (0)              3 (23)             2 (14)             0.83
  Birth data                                                                                                                 
   Preterm delivery, no. (%)                     0 (0)              0 (0)              6 (50)             4 (25)             0.001[*^b^*](#t1n2){ref-type="table-fn"}
   Birthweight, mean (SD), g                     3568 (523)         3249 (408)         3253 (848)         3306 (490)         0.56
  Offspring clinical characteristics                                                                                         
   Age, mean (SD), y                             26.6 (5.3)         25.9 (6.9)         25.4 (6.1)         26.2 (6.6)         0.82
   Body mass index, mean (SD), kg/m^2^           23.0 (2.5)         22.4 (3.1)         23.4 (3.6)         22.9 (3.0)         0.57
   SBP, mean (SD), mm Hg                         125 (11)           117 (16)           126 (14)           120 (14)           0.56
   DBP, mean (SD), mm Hg                         67 (9)             66 (11)            72 (7)             66 (10)            0.39
   Body fat, mean (SD), %                        19.0 (6.1)         29.6 (5.6)         19.5 (5.9)         31.8 (6.3)         0.41
   Waist circumference, mean (SD) cm             84.1 (7.5)         77.2 (7.8)         82.4 (11.1)        74.4 (6.0)         0.35
  Offspring biological characteristics                                                                                       
   Serum creatinine, mean (SD), µmol/L           81 (12)            68 (9)             87 (8)             64 (7)             0.71
   Uricemia, mean (SD), µmol/L                   343 (74)           248 (70)           342 (50)           238 (50)           0.71
   Total cholesterol, mean (SD), mmol/L          4.4 (1.0)          4.6 (0.8)          5.4 (1.2)          4.6 (0.7)          0.097
   Triglycerides, mean (SD), mmol/L              0.87 (0.40)        1.05 (0.44)        1.12 (0.44)        0.86 (0.30)        0.88
   LDL, median (IQR), mmol/L                     2.7 (2.1 to 3.1)   2.8 (2.3 to 3.2)   3.4 (2.7 to 4.4)   2.5 (2.1 to 3.0)   0.14
   HDL, median (IQR), mmol/L                     1.4 (1.3 to 1.6)   1.5 (1.3 to 1.9)   1.5 (1.3 to 1.7)   1.6 (1.5 to 1.7)   0.15

Abbreviations: DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.

*P* value for group effect adjusted for sex.

Adjusted for sex and M value.

###### 

Metabolic Results by Group and Sex

                                                      ODF (n = 29)           ODM (n = 29)                                                         
  --------------------------------------------------- ---------------------- ---------------------- ---------------------- ---------------------- ------------------------------------------
  Oral glucose tolerance test                                                                                                                     
   Fasting plasma glucose, mean (SD), mmol/L          4.7 (0.3)              4.5 (0.3)              4.8 (0.5)              4.4 (0.3)              0.73
   2-h plasma glucose, mean (SD), mmol/L              5.4 (0.9)              6.0 (1.3)              6.1 (1.0)              6.1 (1.8)              0.25
   Fasting plasma insulin, median (IQR), µU/mL        3.1 (2.4--4.4)         4.9 (3.4--6.8)         3.2 (3.1--4.8)         5.2 (3.2--6.0)         0.88
   2-h plasma insulin, median (IQR), µU/mL            15 (10.2--18.7)        29.2 (20.4--45.9)      16.0 (11.6--22.3)      22.4 (18.1--35.6)      0.95
   Early insulin secretion, median (IQR), µU/mmol     10.4 (5.9--14.2)       13.3 (7.6--25.9)       6.0 (3.8--9.4)         9.3 (7.3--13.1)        0.035[*^b^*](#t2n2){ref-type="table-fn"}
  Clamp study                                                                                                                                     
   Adjusted M value, mean (SD), mg/kg/min             11.9 (2.2)             11.5 (2.8)             10.9 (2.6)             11.9 (3.1)             0.74
   Steady-state plasma insulin, median (IQR), µU/mL   104.5 (97.9--115.7)    115.3 (100.8--135.1)   109.6 (101.6--113)     115.9 (100.2--124.7)   0.99
   Insulin-sensitivity index, mean (SD)               0.11 (0.03)            0.11 (0.04)            0.10 (0.02)            0.11 (0.03)            0.46
  Glucose ramping                                                                                                                                 
   Insulin secretion rate, mean (SD), pmol/kg/min     11.2 (5.9)             15.2 (5.1)             12.2 (4.4)             12.5 (4.5)             0.45
  Arginine test                                                                                                                                   
   Plasma glucose pretest, mean (SD), mmol/L          21.5 (3.4)             19.8 (3.0)             21.7 (2.9)             22.6 (2.0)             0.055
   Plasma insulin pretest, median (IQR), µU/mL        57.6 (27.5--85.4)      88.2 (48.7--159.6)     39.6 (25.2--93.8)      46.9 (32.6--74.7)      0.13
   Plasma glucagon pretest, mean (SD), pg/mL          119.8 (38.5)           97.8 (30.5)            108.9 (46.9)           102.7 (40.6)           0.79
   Acute insulin response, median (IQR), µU/mL        235.1 (116.4--302.9)   168.5 (98.6--218.6)    222.2 (172.1--369.1)   230 (152.8--273.6)     0.44
   Acute glucagon response, median (IQR), pg/mL       27.5 (15.2--34.6)      29.8 (10--34.3)        31.4 (12.9--38.4)      23.2 (10.3 to 30.5)    0.37
   Insulin AUC~I-5~, median (IQR), µU/mL              1408 (598--1766)       1061 (830--1660)       957 (716--1930)        1151 (742--1497)       0.37
   Glucagon AUC~I-5~, median (IQR), pg/mL             683 (599--856)         584 (541--675)         628 (610--734)         594 (511--722)         0.19
   Insulin AUC~I-15~, median (IQR), µU/mL             3215 (1527--4291)      2476 (1999--4708)      2268 (1821--5070)      2802 (1802--3601)      0.34
   Glucagon AUC~I-15~, median (IQR), pg/mL            1685 (1592--2337)      1702 (1542--1931)      1710 (1549--2013)      1685 (1472--2057)      0.26

*P* value for group effect adjusted for sex.

Adjusted for sex and M value.

![(A) Early insulin secretion in response to oral glucose. (B) ISR and (C) glucagon secretion suppression in response to IV glucose ramping in male and female ODM and ODF. The early insulin secretion was decreased in ODMs compared with ODFs (*P* = 0.035). The slopes of ISR against plasma glucose was reduced in female ODM compared with ODF (*P* = 0.003), and the slope of glucagon levels against plasma glucose tended to be reduced in female ODM (*P* = 0.07). Data are represented as boxplot showing median and interquartile range. PG, plasma glucose.](js.2017-00482f1){#F1}

3. Discussion {#s4}
=============

The main finding of the current study is that, in response to oral glucose, males and females exposed *in utero* to maternal diabetes exhibit a reduced insulin secretion compared with nonexposed controls. We speculate that these alterations in insulin secretion likely reflect a defect in *β*-cell function, without alteration in *β*-cell mass, because insulin secretion in response to the combination of arginine and glucose, which in theory reflects *β*-cell mass \[[@B11], [@B12]\], was unaffected. In contrast, in response to graded IV glucose infusion, only females (not males) exposed *in utero* to maternal diabetes, exhibit decreased insulin secretion. Therefore, in males, the insulin secretory defect in response to oral glucose is no more present during IV glucose infusion. In response to IV glucose, insulin secretion is mostly dependent on the glucose stimulus of the islet, whereas, in response to oral glucose, insulin secretion is also dependent on gut incretins acting on the gut-brain-islet axis \[[@B13]\]. Together, our results lead us to speculate that, in male and female offspring exposed *in utero* to maternal diabetes, the gut incretin effect may be altered. In contrast, in male offspring exposed *in utero* to maternal diabetes, the direct *β*-cell stimulation of insulin secretion by glucose is preserved. In these males, we also speculate the newly identified insulinotropic action of testosterone via the androgen receptor in *β* cells \[[@B16]\] may compensate for the insulin secretory defect during IV glucose stimulation. Indeed, in absence of *β*-cell androgen receptors, male mice have a defective parenteral glucose-induced insulin secretion.

Our data confirm our previous findings that fetal exposure to maternal T1D diabetes is associated with a reduced insulin secretion in response to oral glucose independent of adiposity and insulin resistance \[[@B3]\]. In contrast, teenage offspring of T1D mothers have been reported to display insulin resistance without decreased insulin secretion in response to oral glucose compared with teenagers from the general population \[[@B17]\]; however, they were heavier than their controls and younger than in our study. In addition the disposition index, the product of insulin sensitivity with insulin secretion was lower, suggesting that the teenage offspring of T1D mothers also had *β*-cell failure.

In this study, a control group of offspring from the general population was not included. Considering the importance of environmental factors in glucose homeostasis, we believe that offspring of T1D fathers were a more representative control group (for offspring of T1D mothers), because the presence of one diabetic parent in a family may induce specific nutritional behaviors affecting the whole family, which would not be observed if the control group comprised a nondiabetic parent from the general population. We acknowledge that we could not quantify retrospectively the level of glycemic control because a majority of pregnancies occurred before 1980, a time when neither glycated hemoglobin nor blood glucose self-monitoring was available for diabetes care. However, the lack of frank macrosomia or microsomia and the birth weights not being different between groups suggest optimized blood glucose control.

In conclusion, fetal exposure to maternal diabetes predisposes to *β*-cell dysfunction in male and female adult offspring. However, this *β*-cell defect is characterized by a sexual dimorphism following IV glucose stimulation, suggesting that males are protected against or can compensate for the deleterious effect of maternal hyperglycemia on fetal *β* cells.
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AUCI

:   incremental area under the curve

ISR

:   insulin secretion rate

IV

:   intravenous

ODF

:   offspring of T1D fathers

ODM

:   offspring of T1D mothers

T1D

:   type 1 diabetes.
